Neuromuscular blocking drugs (NMBDs) do not act in pharmacological isolation. A range of commonly co-administered agents potentiates block through mechanisms that operate presynaptically, postsynaptically, or within the muscle membrane itself. Failure to account for these interactions is a major contributor to postoperative residual neuromuscular blockade (RNMB).

Volatile anesthetic agents – sevoflurane, desflurane, and isoflurane – potentiate non-depolarizing block by multiple mechanisms. At the postsynaptic membrane, they reduce end-plate sensitivity to acetylcholine (ACh), decreasing the amplitude of the end-plate potential (EPP) and lowering the margin of safety of neuromuscular transmission. They also enhance the muscle membrane's sensitivity to the blocking effects of non-depolarizing agents by altering ion channel properties and reducing action potential propagation in muscle fibers. The clinical magnitude of this potentiation is agent- and dose-dependent: desflurane and sevoflurane produce greater potentiation than isoflurane at equivalent minimum alveolar concentration (MAC) values, and potentiation increases with increasing depth of anesthesia.¹ In clinical practice, this means that the dose of non-depolarizing NMBD required to achieve a given depth of block is reduced under volatile anesthesia, and the duration of block is extended compared with total intravenous anesthesia (TIVA). When volatile agents are discontinued at case end, the concurrent reduction in potentiation partially explains the brisk spontaneous recovery that sometimes occurs, but it does not eliminate the need for quantitative monitoring and reversal.

Aminoglycoside antibiotics – gentamicin, tobramycin, amikacin, streptomycin – potentiate non-depolarizing block through presynaptic inhibition of voltage-gated calcium channels (Cav2.1), reducing ACh quantal release per nerve impulse.² They also produce a weak postsynaptic competitive block at the nicotinic acetylcholine receptor (nAChR). The clinical significance of this interaction is greatest when aminoglycosides are administered intraoperatively or in the early postoperative period in patients with residual non-depolarizing block; case reports document prolonged and profound respiratory depression under these circumstances. Calcium gluconate administration can partially reverse aminoglycoside-induced neuromuscular potentiation by restoring presynaptic calcium influx, but this effect is inconsistent and does not replace neostigmine or sugammadex reversal. Polymyxin B and polymyxin E (colistin) share this calcium channel-blocking mechanism and carry the same risk of respiratory failure when administered in the presence of residual block.

Magnesium sulfate, widely used in obstetrics for preeclampsia and eclampsia management and in anesthesia as an adjunct analgesic, potentiates both depolarizing and non-depolarizing NMBDs through two complementary mechanisms. Presynaptically, magnesium inhibits voltage-gated calcium channels, reducing ACh quantal release. Postsynaptically, it competes with calcium at the motor end-plate, further reducing EPP amplitude and lowering the safety margin of transmission.³ Patients receiving magnesium infusions require substantially reduced NMBD doses – approximately 25 to 50 percent reductions are typically necessary – and recovery from block is prolonged. Quantitative neuromuscular monitoring is mandatory in any patient receiving both magnesium and NMBDs. This interaction is particularly clinically relevant in the obstetric ICU setting where magnesium and cisatracurium are commonly co-administered.

Calcium channel blockers of the dihydropyridine class (nifedipine, amlodipine) and the non-dihydropyridine class (verapamil, diltiazem) reduce presynaptic ACh release by attenuating calcium influx through Cav2.1 channels, thereby potentiating non-depolarizing block.⁴ The magnitude of this interaction is generally moderate and is most clinically relevant in patients on chronic calcium channel blocker therapy for hypertension or cardiac disease who receive NMBDs. Local anesthetics, both amide (lidocaine, bupivacaine) and ester (procaine) classes, stabilize axonal and muscle membranes and reduce the amplitude of both the nerve action potential and the muscle action potential, synergizing with non-depolarizing block. Procaine additionally inhibits plasma pseudocholinesterase, further prolonging succinylcholine and mivacurium duration.

Organ failure alters NMBD pharmacokinetics through changes in volume of distribution, plasma protein binding, drug clearance, and active metabolite accumulation. Rational agent selection in patients with organ dysfunction is among the most consequential NMBD dosing decisions in clinical practice.

In renal failure, NMBDs that depend substantially on renal elimination are subject to accumulation and prolonged block. Pancuronium is the most vulnerable agent in this regard, with approximately 80 percent of its elimination occurring as unchanged drug in the urine; in patients with acute kidney injury (AKI) or chronic kidney disease (CKD), pancuronium accumulates and its block may persist for hours beyond the anticipated duration.⁷ Vecuronium undergoes significant renal elimination of its active 3-desacetyl metabolite, and in the ICU setting, accumulation of this metabolite in renal failure patients receiving prolonged vecuronium infusions has produced paralysis lasting days – a clinical syndrome of delayed recovery that was historically confused with ICU-acquired neuromyopathy before the pharmacokinetic mechanism was established. Rocuronium has approximately 10 to 25 percent renal elimination; its duration is modestly prolonged in severe renal failure but does not produce the dramatic accumulation seen with pancuronium or vecuronium's metabolite. Cisatracurium and atracurium undergo Hofmann elimination and plasma esterase hydrolysis that are entirely independent of renal function and represent the safest options for sustained paralysis in the setting of AKI or end-stage renal disease.

Hepatic failure impairs the metabolism and biliary excretion of aminosteroid NMBDs. Rocuronium is primarily eliminated by biliary excretion (approximately 50 percent of the dose excreted unchanged in bile); in severe hepatic disease, biliary flow is reduced and hepatic parenchymal function is impaired, resulting in prolonged rocuronium duration and increased volume of distribution due to reduced plasma protein binding and third-space fluid accumulation.⁸ Vecuronium undergoes hepatic deacetylation to its active metabolite; severe hepatic failure impairs this process and may produce initial resistance (due to reduced first-pass conversion) followed by prolonged block as the parent drug accumulates. Cisatracurium remains the preferred agent in hepatic failure because Hofmann degradation occurs spontaneously in plasma and tissue fluids at physiological pH and temperature, independent of hepatic blood flow or parenchymal function. Atracurium is an acceptable alternative but carries the concern of laudanosine accumulation with high-dose or prolonged infusions, and in patients with combined hepatic and renal failure, laudanosine clearance is further reduced.

Patients with combined organ failure present a particular challenge because the kinetic parameters governing NMBD distribution and elimination are simultaneously deranged in multiple directions. Increased volume of distribution due to edema, capillary leak, and resuscitation fluids requires higher initial loading doses to achieve target plasma concentrations; reduced clearance due to impaired hepatic and renal function prolongs duration; altered plasma protein binding changes the free drug fraction; and continuous renal replacement therapy (CRRT) may remove some fraction of water-soluble agents. For all these reasons, sustained paralysis in the ICU should use cisatracurium whenever possible, with dose titration guided by quantitative train-of-four monitoring rather than fixed infusion rates.⁹

Prolonged neuromuscular blockade in the ICU is associated with ICU-acquired weakness (ICUAW), a syndrome of diffuse muscle weakness that persists beyond the resolution of the underlying illness and is associated with prolonged mechanical ventilation, increased ICU length of stay, and long-term functional impairment. Understanding the relationship between NMBD use and ICUAW is essential for responsible prescribing in the ICU.

ICU-acquired weakness encompasses three overlapping entities: critical illness polyneuropathy (CIP), critical illness myopathy (CIM), and critical illness neuromyopathy (CINM), where both neuropathic and myopathic components are present simultaneously. CIM is the form most directly linked to pharmacological neuromuscular blockade, though prolonged bed rest, systemic inflammation, corticosteroids, and sepsis independently contribute to its development. The pathophysiology of CIM includes loss of myosin thick filaments, muscle membrane channelopathy producing electrical inexcitability, and oxidative muscle injury. Prolonged NMBD administration creates chemical denervation of the muscle membrane, which triggers the same upregulatory and structural changes seen in physical denervation: loss of mature nAChR expression, proliferation of extrajunctional fetal-type nAChRs, and progressive muscle atrophy.¹³

The ACURASYS trial (2010) established that a 48-hour infusion of cisatracurium in early severe acute respiratory distress syndrome (ARDS), as defined by a PaO2/FiO2 ratio below 150, improved 90-day adjusted mortality and increased ventilator-free days without worsening muscle weakness as assessed at day 28.¹⁴ This finding provided the evidence base for short-duration cisatracurium use in early severe ARDS and established cisatracurium as the preferred agent for ICU paralysis. However, the subsequent ROSE trial (2019) failed to replicate the mortality benefit of routine early neuromuscular blockade in ARDS when compared with a light sedation strategy using modern sedation protocols, calling into question the routine application of 48-hour cisatracurium in all ARDS patients and limiting its evidence-based indications to those with persistent severe hypoxemia refractory to other interventions.¹⁵

Risk factors for ICUAW include sepsis and septic shock, prolonged mechanical ventilation, systemic corticosteroids, aminoglycosides, prolonged NMBD infusions, hyperglycemia, and the severity of the underlying critical illness. These risk factors are frequently concurrent in the same patient, making it impossible to attribute ICUAW to NMBDs alone in any individual case. However, minimizing the duration of NMBD administration – using the briefest effective course, interrupting infusions when clinical goals are met, and resuming only when re-indicated – is the primary modifiable intervention available to the prescribing clinician. All patients receiving NMBDs in the ICU should have train-of-four count monitored at regular intervals to prevent overly deep block; a TOF count of 1 to 2 out of 4 is generally the target range for patients requiring continued paralysis, sufficient to achieve clinical goals while preserving the minimum neuromuscular function that limits ICUAW risk.

Monitoring of patients in the ICU receiving NMBDs presents practical challenges distinct from the operating room setting. Quantitative acceleromyography is less practical in the ICU environment, and qualitative TOF assessment is more commonly used. Clinical monitoring of the level of sedation is equally important, as NMBDs must never be administered without adequate concurrent sedation – a paralyzed but conscious patient represents one of the most serious preventable adverse events in critical care medicine. Daily spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs) should be coordinated, and NMBD infusions should be discontinued during these trials whenever the clinical condition permits. When NMBDs are discontinued, patients should be reassessed for ICUAW by physiotherapy within 24 to 48 hours of return of voluntary movement, enabling early mobilization where possible.